TY - JOUR
T1 - Management and outcomes of adolescent and young adult sarcoma patients
T2 - results from the French nationwide database NETSARC
AU - Kubicek, Pierre
AU - Cesne, Axel Le
AU - Lervat, Cyril
AU - Toulmonde, Maud
AU - Chevreau, Christine
AU - Duffaud, Florence
AU - Le Nail, Louis Romée
AU - Morelle, Magali
AU - Gaspar, Nathalie
AU - Vérité, Cécile
AU - Castex, Marie Pierre
AU - Penel, Nicolas
AU - Saada, Esma
AU - Causeret, Sylvain
AU - Bertucci, François
AU - Perrin, Christophe
AU - Bompas, Emmanuelle
AU - Orbach, Daniel
AU - Laurence, Valérie
AU - Piperno-Neumann, Sophie
AU - Anract, Philippe
AU - Rios, Maria
AU - Gentet, Jean Claude
AU - Mascard, Éric
AU - Pannier, Stéphanie
AU - Blouin, Pascale
AU - Carrère, Sébastien
AU - Chaigneau, Loïc
AU - Soibinet-Oudot, Pauline
AU - Corradini, Nadège
AU - Boudou-Rouquette, Pascaline
AU - Ruzic, Jean Christophe
AU - Lebrun-Ly, Valérie
AU - Dubray-Longeras, Pascale
AU - Varatharajah, Sharmini
AU - Lebbe, Céleste
AU - Ropars, Mickaël
AU - Kurtz, Jean Emmanuel
AU - Guillemet, Cécile
AU - Lotz, Jean Pierre
AU - Berchoud, Juliane
AU - Cherrier, Grégory
AU - Ducimetière, Françoise
AU - Chemin, Claire
AU - Italiano, Antoine
AU - Honoré, Charles
AU - Desandes, Emmanuel
AU - Blay, Jean Yves
AU - Gouin, François
AU - Marec-Bérard, Perrine
N1 - Publisher Copyright:
© 2023, The Author(s).
PY - 2023/12/1
Y1 - 2023/12/1
N2 - Background: The initial management of patients with sarcoma is a critical issue. We used the nationwide French National Cancer Institute-funded prospective sarcoma database NETSARC to report the management and oncologic outcomes in adolescents and young adults (AYAs) patients with sarcoma at the national level. Patients and methods: NETSARC database gathers regularly monitored and updated data from patients with sarcoma. NETSARC was queried for patients (15–30 years) with sarcoma diagnosed from 2010 to 2017 for whom tumor resection had been performed. We reported management, locoregional recurrence-free survival (LRFS), progression-free survival (PFS), and overall survival (OS) in AYA treated in French reference sarcoma centers (RSC) and outside RSC (non-RSC) and conducted multivariable survival analyses adjusted for classical prognostic factors. Results: Among 3,227 patients aged 15–30 years with sarcoma diagnosed between 2010 and 2017, the study included 2,227 patients with surgery data available, among whom 1,290 AYAs had been operated in RSC, and 937 AYAs in non-RSC. Significant differences in compliance to guidelines were observed including pre-treatment biopsy (RSC: 85.9%; non-RSC 48.1%), pre-treatment imaging (RSC: 86.8%; non-RSC: 56.5%) and R0 margins (RSC 57.6%; non-RSC: 20.2%) (p < 0.001). 3y-OS rates were 81.1% (95%CI 78.3–83.6) in AYA in RSC and 82.7% (95%CI 79.4–85.5) in AYA in non-RSC, respectively. Whereas no significant differences in OS was observed in AYAs treated in RSC and in non-RSC, LRFS and PFS were improved in AYAs treated in RSC compared to AYAs treated in non-RSC (Hazard Ratios (HR): 0.58 and 0.83, respectively). Conclusions: This study highlights the importance for AYA patients with sarcoma to be managed in national sarcoma reference centers involving multidisciplinary medical teams with paediatric and adult oncologists.
AB - Background: The initial management of patients with sarcoma is a critical issue. We used the nationwide French National Cancer Institute-funded prospective sarcoma database NETSARC to report the management and oncologic outcomes in adolescents and young adults (AYAs) patients with sarcoma at the national level. Patients and methods: NETSARC database gathers regularly monitored and updated data from patients with sarcoma. NETSARC was queried for patients (15–30 years) with sarcoma diagnosed from 2010 to 2017 for whom tumor resection had been performed. We reported management, locoregional recurrence-free survival (LRFS), progression-free survival (PFS), and overall survival (OS) in AYA treated in French reference sarcoma centers (RSC) and outside RSC (non-RSC) and conducted multivariable survival analyses adjusted for classical prognostic factors. Results: Among 3,227 patients aged 15–30 years with sarcoma diagnosed between 2010 and 2017, the study included 2,227 patients with surgery data available, among whom 1,290 AYAs had been operated in RSC, and 937 AYAs in non-RSC. Significant differences in compliance to guidelines were observed including pre-treatment biopsy (RSC: 85.9%; non-RSC 48.1%), pre-treatment imaging (RSC: 86.8%; non-RSC: 56.5%) and R0 margins (RSC 57.6%; non-RSC: 20.2%) (p < 0.001). 3y-OS rates were 81.1% (95%CI 78.3–83.6) in AYA in RSC and 82.7% (95%CI 79.4–85.5) in AYA in non-RSC, respectively. Whereas no significant differences in OS was observed in AYAs treated in RSC and in non-RSC, LRFS and PFS were improved in AYAs treated in RSC compared to AYAs treated in non-RSC (Hazard Ratios (HR): 0.58 and 0.83, respectively). Conclusions: This study highlights the importance for AYA patients with sarcoma to be managed in national sarcoma reference centers involving multidisciplinary medical teams with paediatric and adult oncologists.
KW - AYAs
KW - Adolescents and young adults
KW - Management
KW - Multidisciplinary tumor board
KW - NETSARC
KW - Reference centers
KW - Sarcoma
KW - Survival
UR - http://www.scopus.com/inward/record.url?scp=85146569788&partnerID=8YFLogxK
U2 - 10.1186/s12885-023-10556-4
DO - 10.1186/s12885-023-10556-4
M3 - Article
C2 - 36670431
AN - SCOPUS:85146569788
SN - 1471-2407
VL - 23
JO - BMC Cancer
JF - BMC Cancer
IS - 1
M1 - 69
ER -